Citryll is at the forefront of developing innovative therapies aimed at treating immune-mediated inflammatory diseases by specifically targeting Neutrophil Extracellular Traps (NETs). Their lead product, CIT-013, is a first-in-class monoclonal antibody that operates through a unique dual mode of action. This therapeutic agent has shown significant potential in inhibiting the formation of NETs while enhancing their clearance, addressing a critical factor in the inflammatory process. Citryll's focus on NETs is particularly relevant in conditions such as Rheumatoid Arthritis and Hidradenitis Suppurativa, where excessive NET formation contributes to chronic inflammation and tissue damage.

The company is advancing CIT-013 through various clinical development stages, with promising results from Phase 1 trials indicating its safety and tolerability in both healthy volunteers and patients with rheumatoid arthritis. The therapeutic approach of targeting citrullinated histones, a hallmark of NETs, positions Citryll as a leader in the field of NET-driven inflammation. As they prepare to initiate Phase 2a studies in 2025, Citryll aims to expand its research into other immune-mediated inflammatory diseases, further solidifying its commitment to addressing unmet medical needs in this area.

Netherlands

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Citryll

Company Details